CytoMed Therapeutics (GDTC) Payables (2021 - 2025)

CytoMed Therapeutics has disclosed Payables across 5 years of filings, most recently posting $373994.6 for Q4 2025.

• In Q4 2025, Payables rose 3.93% year-over-year to $373994.6; the TTM figure through Dec 2025 stood at $373994.6 (up 3.93% YoY), while the FY2025 annual figure was $371500.2, up 3.45% from the prior year.
• Payables came in at $373994.6 for Q4 2025 at CytoMed Therapeutics, down from $477690.0 in the prior quarter.
• In the past five years, Payables ranged from a high of $541269.6 in Q4 2022 to a low of $266892.0 in Q2 2023.
• Average Payables over 5 years is $399377.7, with a median of $393854.2 recorded in 2023.
• Year-over-year, Payables slipped 23.57% in 2023 and soared 51.07% in 2025.
• Over 5 years, Payables stood at $445393.4 in 2021, then rose by 21.53% to $541269.6 in 2022, then fell by 23.57% to $413713.8 in 2023, then retreated by 13.02% to $359855.1 in 2024, then climbed by 3.93% to $373994.6 in 2025.
• Per Business Quant data, the three most recent Payables figures were $373994.6 in Q4 2025, $477690.0 in Q2 2025, and $359855.1 in Q4 2024.